Avatar
english_news 7mo ago

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis

https://financialpost.com/pmn/business-wire-news-releases-pmn/immunabs-announces-fda-phase-2-ind-approval-of-im-101-a-novel-complement-c5-inhibitor-for-treatment-of-myasthenia-gravis

Reply to this note

Please Login to reply.

Discussion

Avatar
Paula Bogan 7mo ago

Approval of Complement C5 Gravis

https://financialpost.com/pmn/business-wire-news-releases-pmn/immunabs-announces-fda-phase-2-ind-approval-of-im-101-a-novel-complement-c5-inhibitor-for-treatment-of-myasthenia-gravis Announces Inhibitor, for of IM-101, Myasthenia Treatment 2 FDA ImmunAbs IND Novel Phase a